Back to news

Apnimed Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Globe Newswire•16/11/2026•08:00 ET
1

Key Highlights

  • ➤$351.8 million cash and equivalents expected to fund operations into Q2 2028
  • ➤AD109 NDA remains under FDA review with February 28, 2027 PDUFA goal date
  • ➤$29.5 million quarterly net loss widened from $10.9 million year over year
  • ➤General and administrative expenses rose 100% to $22.6 million
  • ➤$198.9 million net proceeds raised in August upsized IPO

Expert Statements

Kevin Lind, Chief Executive Officer of Apnimed

“We are in a transformational period at Apnimed. With our NDA for AD109 (proposed proprietary name Oxnimbi) under FDA review and a PDUFA goal date of February 28, 2027, we are advancing our launch readiness while continuing to strengthen the clinical story. At CHEST, we presented new analyses in postmenopausal women, on baseline hypoxic burden as a potential marker of blood pressure response, and on patient-reported outcomes. We believe this growing body of evidence is important to establishing the potential role of Oxnimbi for the millions of adults with OSA who remain untreated.”

* New Drug Application (“NDA”) for AD109, with a proposed proprietary name Oxnimbi™ (aroxybutynin and atomoxetine) tablets, for oral use, remains under U.S. Food and Drug Administration (“FDA”) review with a February 28, 2027, Prescription Drug User Fee Act (“PDUFA”) goal date * Commercial readiness activities advance in preparation for a potential U.S. launch * Presented five abstracts at CHEST 2026, including two late-breakers, highlighting AD109 Phase 3 clinical data and the burden of OSA * $351.8 million in cash and cash equivalents as of September 30, 2026, expected to fund the potential U.S. launch of Oxnimbi and operations into the second quarter of 2028 CAMBRIDGE, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced its financial results for the third quarter ended September 30, 2026, and provided a corporate update.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in